Health
Melatonin could act as barrier against SARS-CoV-2 infection – Drug Target Review
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
Posted: 28 January 2021 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
According to a new study, melatonin synthesised in the lungs could act as a barrier against SARS-CoV-2, preventing expression of genes that encode proteins in cells such as resident macrophages in the nose and pulmonary alveoli and epithelial cells lining the alveoli, all of which…
Continue Reading
